Simcere Pharma (02096) has issued a circular detailing resolutions to be tabled at its annual general meeting (AGM) scheduled for 9:00 a.m. on 12 June 2026 in Shanghai.

Key proposals:

1. Capital mandates • General mandate: Directors seek authority to issue up to 20% of issued share capital, equal to 519.14 million shares based on the 2,595.70 million shares outstanding on the latest practicable date (18 May 2026). • Repurchase mandate: Authority to buy back up to 10% of issued shares, or 259.57 million shares. Repurchased shares may be cancelled; the company does not currently plan to hold them as treasury stock.

2. Final dividend • Recommended payout of RMB0.18 per share for FY 2025, translating to an estimated RMB467.23 million distribution. • Record date: 24 June 2026; expected payment on or before 13 July 2026.

3. Board composition • Re-election of Executive Directors Mr Tang Renhong and Mr Wan Yushan, and Independent Non-executive Director Mr Song Ruilin. • Reappointment of KPMG as auditor for FY 2026; audit fee estimated at RMB4.20 million–RMB4.40 million.

4. Articles of Association • Proposed adoption of a new set of articles to: – Align with Hong Kong Stock Exchange core shareholder protection standards, including provisions for virtual general meetings; – Permit holding of treasury shares under the updated Hong Kong Companies Ordinance; – Incorporate housekeeping amendments.

Important dates: • Share register closed 9–12 June 2026 (both days inclusive) for AGM attendance. • Share register closed 19–24 June 2026 for dividend entitlement.

If approved, all resolutions will take effect immediately following the AGM.